Speech Quest Jcny Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 581 Jersey Ave, Jersey City, NJ 07302 Phone: 201-381-1607 Fax: 201-216-9171 |
Mr. Josephus Reynes Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 54 Towers St, Jersey City, NJ 07305 Phone: 917-226-1181 |
Alisha Beth Cipollone, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 299 Pavonia Avenue, 1-3, Jersey City, NJ 07302 Phone: 917-478-3042 |
Maria Pasahol, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 Journal Square Plz, Jersey City, NJ 07306 Phone: 551-247-1306 |
Katie Michele Hanily, M.A. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 Journal Square Plz Ste 610, Jersey City, NJ 07306 Phone: 551-247-1306 |
Sensorykids,llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 278 Monmouth St, Jersey City, NJ 07302 Phone: 201-324-1700 |
Elizabeth Bornstein Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 263 Whiton St Apt 2, Jersey City, NJ 07304 Phone: 908-625-2550 Fax: 908-232-3583 |
Ms. Amanda G Alvarez, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 206 Washington St Apt 4b, Jersey City, NJ 07302 Phone: 201-481-0745 |
Your Journey - Speech & Language Therapy Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 550 Summit Ave Ste B1, Jersey City, NJ 07306 Phone: 201-878-4296 |
Dana Kaminsky, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 Journal Square Plz Ste 610, Jersey City, NJ 07306 Phone: 551-247-1306 |
Delta Speech Therapy, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12 Holly St, Jersey City, NJ 07305 Phone: 551-225-0413 |
Marielvi Reyes Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 25 Van Wagenen Ave Apt 1r, Jersey City, NJ 07306 Phone: 201-306-7385 |
Nicole Spielsinger Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 98 Wayne St, Jersey City, NJ 07302 Phone: 201-655-2379 |
Morgan Felix, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 401 Washington Blvd Apt 3507, Jersey City, NJ 07310 Phone: 908-670-0288 |
Grow With Me Speech Therapy Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Apollo St Fl 1, Jersey City, NJ 07306 Phone: 908-692-7998 |
Mr. Daniel Eugene Wilson, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 75 Liberty Ave, #a20, Jersey City, NJ 07306 Phone: 201-963-3331 |
Nadia Farooq, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Christopher Columbus Dr, Apt 603, Jersey City, NJ 07302 Phone: 516-476-0404 |
Konstantina Terranova, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4 Beacon Way, Suite 1504, Jersey City, NJ 07304 Phone: 201-918-4585 |
Logos Speech Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 129 Newark Ave, Jersey City, NJ 07302 Phone: 201-451-8867 |
Dustin Smith, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 128 Chestnut Ave # 2, Jersey City, NJ 07306 Phone: 973-460-6533 |
News Archive
In a recent study, a team of researchers aimed to investigate the prevalence and predictors of fibromyalgia in patients who recovered from COVID-19.
Medical professionals at Cincinnati Children's Hospital Medical Center want to make sure that families and children stay safe this spring while participating in spring cleaning.
Sigma-Tau Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's new drug application (NDA) for its cysteamine hydrochloride ophthalmic solution, an investigational therapy for the treatment of corneal cystine crystals in patients with cystinosis. The FDA also granted the NDA Priority Review status, a designation given to drugs that may provide major advances or a treatment where no adequate therapy exists.
Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.
› Verified 2 days ago